The Prevalence and Distribution of Vitreoretinal Interface Abnormalities among Urban Community Population in China
Table 4
The prevalence of VIAs within females in this study (number of eyes or %).
Variables
Type 2 diabetes patients
Normal subjects (number of eyes)
45–54 years
55–64 years
≥65 years
value
Total
45–54 years
55–64 years
≥65 years
value#
Total
value†
ERM
5 (4.31)
15 (13.39)
25 (21.55)
<0.01
45 (13.08)
7 (7.14)
9 (7.89)
11 (8.87)
0.89
27 (8.03)
0.03
PTMH
1 (0.86)
1 (0.89)
1 (0.86)
3 (0.87)
0
0
1 (0.81)
1 (0.29)
0.63
FTMH
1 (0.86)
0
2 (1.72)
3 (0.87)
0
2 (1.75)
1 (0.81)
3 (0.89)
0.73
VMT
4 (3.44)
6 (5.36)
9 (7.76)
0.35
19 (5.52)
3 (3.06)
4 (3.51)
6 (4.84)
0.76
13 (3.87)
0.31
MC/ME
3 (2.58)
5 (4.46)
14 (12.07)
<0.01
22 (6.39)
0
3 (2.63)
7 (5.65)
10 (2.98)
0.03
PVD
5 (4.31)
7 (6.25)
10 (8.62)
0.40
22 (6.39)
8 (8.16)
9 (7.89)
12 (9.68)
0.87
29 (8.63)
0.26
VIAs
19 (16.38)
34 (30.35)
61 (52.59)
<0.01
114 (33.14)
18 (18.37)
27 (23.68)
38 (30.64)
<0.01
83 (24.70)
<0.01
Epiretinal membrane without schisis (ERM); macular cysts/macular edema (MC/ME); partial thickness macular hole (PTMH); full-thickness macular hole (FTMH); posterior vitreous detachment (PVD); vitreomacular traction syndrome (VMT). Difference analysis between three age groups in Type 2 diabetes patients. #Difference analysis between three age groups in normal subjects. †Difference analysis between Type 2 diabetes patients and normal subjects groups.
